Modulation of pde11a activity
CA 2360485 A1 · Owner: Pfizer Inc. · Inventors: Lanfear, Jeremy; Burslem, Martyn Frank; Phillips, Stephen Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a functionally disrupted PDE11A gene. Also provided by the invention are methods of screening for agents that modulate, PDE11A to modulate spermatogenesis methods of treating mammals to modulate spermatogenesis, and methods of modulating cAMP and cGMP signal transduction in cells that express PDE11A.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.